Vanguard Personalized Indexing Management LLC Raises Position in Inspire Medical Systems, Inc. $INSP

Vanguard Personalized Indexing Management LLC lifted its stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 29.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,360 shares of the company’s stock after purchasing an additional 538 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Inspire Medical Systems were worth $306,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of INSP. Quarry LP increased its stake in shares of Inspire Medical Systems by 2,127.3% during the 1st quarter. Quarry LP now owns 245 shares of the company’s stock worth $39,000 after purchasing an additional 234 shares during the last quarter. Banque Transatlantique SA purchased a new stake in shares of Inspire Medical Systems during the 1st quarter worth approximately $46,000. Smartleaf Asset Management LLC increased its stake in shares of Inspire Medical Systems by 27.2% during the 1st quarter. Smartleaf Asset Management LLC now owns 454 shares of the company’s stock worth $71,000 after purchasing an additional 97 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Inspire Medical Systems by 14.6% in the 2nd quarter. Farther Finance Advisors LLC now owns 603 shares of the company’s stock valued at $78,000 after buying an additional 77 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Inspire Medical Systems by 253.7% in the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company’s stock valued at $91,000 after buying an additional 411 shares in the last quarter. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Insider Buying and Selling

In other Inspire Medical Systems news, CFO Richard Buchholz sold 11,000 shares of the firm’s stock in a transaction on Friday, August 29th. The shares were sold at an average price of $93.39, for a total value of $1,027,290.00. Following the completion of the transaction, the chief financial officer directly owned 44,867 shares of the company’s stock, valued at $4,190,129.13. This trade represents a 19.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.10% of the stock is currently owned by insiders.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $77.45 on Friday. The firm has a fifty day moving average price of $82.44 and a two-hundred day moving average price of $116.66. Inspire Medical Systems, Inc. has a one year low of $70.77 and a one year high of $216.01. The company has a market cap of $2.29 billion, a price-to-earnings ratio of 44.77, a PEG ratio of 2.50 and a beta of 1.16.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. The firm had revenue of $217.09 million during the quarter, compared to the consensus estimate of $214.50 million. During the same period last year, the firm earned $0.32 EPS. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. Equities research analysts expect that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems announced that its board has initiated a share repurchase program on Monday, August 11th that authorizes the company to buyback $200.00 million in shares. This buyback authorization authorizes the company to purchase up to 8.6% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on INSP shares. JPMorgan Chase & Co. lowered shares of Inspire Medical Systems from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $195.00 to $110.00 in a research note on Tuesday, August 5th. Evercore ISI reduced their price objective on shares of Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 7th. Leerink Partners reduced their price objective on shares of Inspire Medical Systems from $116.00 to $97.00 and set a “market perform” rating for the company in a research note on Friday, August 15th. Piper Sandler reduced their price objective on shares of Inspire Medical Systems from $233.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, August 5th. Finally, Lake Street Capital set a $150.00 price objective on shares of Inspire Medical Systems and gave the company a “buy” rating in a research note on Tuesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inspire Medical Systems has an average rating of “Hold” and an average target price of $141.13.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.